GlobeNewswire by notified

CGFNS International Reaffirms Its Commitment to Combatting Fraud in Nurse Credentialing

Share

PHILADELPHIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- In the wake of federal charges related to large-scale schemes to sell fake nursing diplomas at some U.S. nursing schools, CGFNS International, a global leader in international credentials evaluation to support health worker mobility, has bolstered its efforts to combat fraud and ensure patient safety through the assessment and authentication of credentials.

Leaders at the organization, which has 45 years of experience in evaluating international education credentials for foreign-trained health workers, pointed to the global nursing shortage as a key driver of increased fraud.

"CGFNS is actively reviewing whether any of the reports we issued are impacted," said CGFNS President and Chief Executive Officer Dr. Peter Preziosi. "If we find evidence of this, we will move quickly to address it."

"An honestly-earned education paired with appropriate clinical experience is a prerequisite for nursing licensure and is absolutely essential to protecting public safety and trust in the healthcare professions. This applies to all health professionals regardless of whether education was received domestically or internationally," he said.

As a preventive measure to combat fraud, CGFNS requires transcripts and validations of licenses to be sent directly from primary source institutions, and it maintains a database of school and licensing officials who are authorized to send documents to CGFNS. The organization catalogues the signatures of these officials as well as their institutional seals or stamps.

Preziosi said that CGFNS, as a longstanding partner of nurse regulators, accreditation agencies, and licensing test providers, will aim to further increase collaboration among the credentialing community to increase vigilance and combat fraud. The organization will also be reviewing its internal security practices to ensure up-to-date, robust protections are in place during the assessment of education and licensing documents of the migrant nurses utilizing its programs.

"In light of this discovery, CGFNS will continue to make every effort to ensure the quality and integrity of the nurses it supports and to uphold the integrity of the global healthcare workforce," he said.

About CGFNS International, Inc.
Founded in 1977 and based in Philadelphia, CGFNS International is an immigration-neutral not-for-profit organization proudly serving as the world's largest credentials evaluation organization for the nursing and allied health professions. For more information, visit www.cgfns.org.

Contact Information:
Mukul Bakhshi, Esq.
Chief of Strategy and Government Affairs
mbakhshi@cgfns.org
(215) 243-5825

Related Images



To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.


Image 1: CGFNS International



This content was issued through the press release distribution service at Newswire.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter24.4.2024 07:00:00 CEST | Press release

Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs. Fine Chemicals had a lower result due to low bioethanol deliveries and increased costs. The net currency effects were slightly negative for the Group. Profit before tax was NOK 261 million (NOK 292 million). Earnings per share were NOK 2.01 (NOK 2.32). - We are pleased with the strong result improvement in BioSolutions and the positive sales volume development for the Group, says President and CEO Per A. Sørlie. Contacts: Director Investor Relations, Knut-Harald Bakke, +47 905 79 164 Director Communicat

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-1924.4.2024 07:00:00 CEST | Press release

Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A). Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine Ronapreve Diagnostics Division base business2 grew by 8%, supported by growth across all regions because of demand for immunodiagnostic products, clinical chemistry tests and advanced staining solutions. As this growth was partially offset by the lower dem

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates24.4.2024 07:00:00 CEST | Press release

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant improvement in kidney function observed with varoglutamstat 600mg BID in VIVIAD over two years based on pre-specified analysis of the estimated glomerular filtration rateCompany plans to explore potential of varoglutamstat in kidney disease in a shift of strategic focus towards inflammatory and fibrotic disorders VIVA-MIND Phase 2 study to be discontinued early, in H2 2024, which will enable accelerated data analysis and inform varoglutamstat development strategyCompany is taking steps to reduce cash utilizatio

Wereldhave Trading update Q1 202424.4.2024 07:00:00 CEST | Press release

Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some bankruptciesLeasing spreads in the Netherlands moving into positive territoryRent collection >97% underpinning tenant qualityLTV improved to 41.5% due to positive Belgian revaluations (ERV driven) and targeted CAPEXUpdate on short-term strategic focus: rotating capital out of the Netherlands to further reduce LTVFull Service Center Sterrenburg awarded with the 2024 Kern annual development awardForecast FY 2024 DRPS € 1.75 reiterated Attachment Trading update Q1 2024 Wereldhave N.V.

IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma24.4.2024 07:00:00 CEST | Press release

ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U, a European distributor in the pharmaceutical and nutraceutical industry. Established in 2011 and headquartered in Barcelona, Spain, Cobapharma provides an extensive portfolio of Active Pharmaceutical Ingredients (APIs) as well as nutraceutical ingredients. With 20 employees, Cobapharma represents leading suppliers and generated a revenue of approximately EUR 19 million in the financial year that ended December 31, 2023. ‘Cobapharma is a rapidly growing distributor in the pharmaceutical and nutraceutical industry. Their esteemed reputation for providing high-quality APIs and nutraceutical ingredients perfectly complements our existing portfolio. The alignment of our business models will enhance our ability to serve our customers and partners’ c

HiddenA line styled icon from Orion Icon Library.Eye